Analysis of Drugs Approved by FDA in Recent Years

Abstract

Abstract: ObjectiveTo analyze drugs approved by FDA in recent years, and provide references for developing and approving drugs in China. MethodsThis article analyzes the number, review timeline and therapeutic area of drugs approved in America by literature. Resultsand ConclusionThe number of drugs approved by FDA has increased recently, the review timeline is shortened, and they have improved their focus on orphan drug, pediatric drug, cancer area, neurological and psychiatric disease and so on. Our country can refer to the drugs FDA has approved, and improve the policies of drugs approving to facilitate the development of new drugs and generic drugs.

Key words: FDA, marketed drugs, number, therapeutic area, review timeline

CLC Number:

R951

REN Yu, YANG Yue. Analysis of Drugs Approved by FDA in Recent Years[J]. Chinese Journal of Pharmacovigilance, 2014, 11(5): 275-280.

References

[1] FDA. New Molecular Entity 2010 Statistics[EB/OL]. [2014-03-01].http://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprov-alreports/ucm242695.pdf.
[2] IMS. Top Corporation by Prescriptions Total RX in millions[EB/OL].(2011-04-07)[2014-03-01]. http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press20Room/Top-line%20Market%20Data/2010%20Top-line%20Market%20Data/2010_Top_
Corporations_by_RX.pdf.
[3] FDA .Facts about Generic Drugs [EB/OL]. (2012-09-19)[2014-03-01].http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm167991.htm .
[4] 唐健元,赵夏茵. 国外孤儿药管理制度对比研究及对我国的政策建议[J]. 中国新药杂志, 2013,22(14):1638-1642.
[5] Marlene E. Haffner, Janet Whitley, Marie Moses.Two decades of orphan product development[J]. Nature Reviews Drug Discovery, 2002, 1（10）: 821-825.
[6] FDA. Pediatric Exclusivity Granted[EB/OL].(2014-02-05) [2014-03-01].http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/ucm050005.htm.
[7] 成殷,邵蓉. 美国儿科药品审批政策概述[J]. 中国执业药师,2012,9(05):43-46.
[8] IMS. Top 20 Global Therapeutic Classes, 2010, Total Audited Markets[EB/OL]. [2014-03-01]. http://www.ims.com.
[9] FDA. FY 2011: performance report to the president and congress for the Prescription Drug User Fee Act[EB/OL].(2012-03-01) [2014-03-01]. http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/PDUFA/UCM294101.pdf.
[10] FDA. Guidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day[EB/OL]. (2003-07) [2014-03-01]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072851.pdf.
[11] Garth Boehm,姚立新,郑强. 企业付费法案与仿制药产业发展[J]. 中国新药杂志,2013,22(02):150-158.
[12] Garth Boehm,姚立新,郑强. FDA公布2014财年仿制药企业付费修正案(GDUFA)付费标准[J]. 中国新药杂志,2013,22(18):2140-2141.

[1]	YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing. Safety of sugammadex for reversal of neuromuscular block based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
[2]	HAO Xiaohui, ZHANG Ping, WU Lulu, WANG Lihua. Mining and analysis of ixazomib citrate capsules safety signals based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1427-1431.
[3]	REN Yuqin, LI Xin, YU Min, SU Yuwen. Safety evaluation and comparative analysis of rituximab and adalimumab based on openFDA [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 752-756.
[4]	ZHANG Chi. Data mining of adverse drug events of alirocumab from openFDA [J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 684-691.
[5]	CUI Xiangli, ZHANG Zhiqi, SUN Liying, GUO Mingxing, ZENG Zhigui, XU Wanyi. Leflunomide-induced hepatotoxicity: data analysis based on the FDA adverse event reporting system [J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 426-431.
[6]	ZHAO Xiaohong, GUO Mingxing, WANG Xiaojian, LIN Jianrui, CUI Xiangli. Risk signal mining related to lenvatinib based on the US FDA adverse event reporting system [J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1233-1237.
[7]	SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu. Research and reflection on regulatory science developments of U.S. FDA [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
[8]	LIU Jing, YE Guoju, WANG Qiming, LIU Wei, ZHAO Dafang, SUN Jun, LI Guoliang, WANG Xinmin, LI Ming. Detection of report signals of adverse drug reactions by fuzzy BCPNN [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1113-1117.
[9]	LING Tao, XU Ruijuan, GE Weihong. Comparison Analysis of Adverse Drug Reactions of Rivaroxaban and Apixaban Based on OpenFDA [J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 780-783.
[10]	LI Jiangfan, HU Ye, PANG Hongxian, ZHAO Dan, LI Xinru, WANG Xuhong. Comparative Analysis of Adverse Drug Reactions of Evolocumab and Alirocumab Based on OpenFDA [J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 965-968.
[11]	WEI Fuqian, ZHANG Wei, YANG Yue. Drug Risk Communication between Drug Regulatory Agencies and the Public [J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 949-952.
[12]	WEI Fuqian, ZHANG Wei, YANG Yue. Implementation of US FDA's Drug Risk Evaluation and Mitigation Strategies [J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 871-876.
[13]	WANG Linlin, YANG Yue, WANG Shuling. Application of the US FDA Sentinel System and Enlightenment [J]. Chinese Journal of Pharmacovigilance, 2019, 16(2): 81-87.
[14]	BAO Cheng-cheng, WANG Hong-wei, YANG Yue. Consideration on Implementation and Reference Through FDA Risk Evaluation and Mitigation Strategy [J]. Chinese Journal of Pharmacovigilance, 2017, 14(5): 283-288.
[15]	SHI Wen-hui, CHEN Ying, YAO Jie, SUN Zhi-ming, XU Hao-qin. Study on Drospirenone and Ethinylestradiol Tablets Using FDA Public Data Program [J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 552-555.